Introduction {#Sec1}
============

Obesity is mainly characterized by adipocyte hypertrophy (increase in fat cell size) and the accumulation of adipose tissue macrophages (ATMs) in humans and rodents, which induce chronic, low-grade inflammation, and insulin resistance (IR) \[[@CR1]\]. In obese adipose tissue, ATMs undergo polarization from the M2 (anti-inflammatory) to M1 (pro-inflammatory) phenotype, which is considered a biomarker of macrophage-driven adipose tissue inflammation in IR, with elevated F4/80^+^ and CD11c^+^ M1-like macrophages \[[@CR2]\]. Hypertrophied adipocytes and immune cells, such as M1-like macrophages, shift the secretion of cytokines and adipokines toward the inflammatory profile (e.g., MCP-1 and IL-6) \[[@CR3]\], leading to the impairment of insulin sensitivity through activation of pro-inflammatory signaling, such as activation of TLR-4 and NF-κB \[[@CR4]\]. Furthermore, the depletion of CD11c^+^ M1-like macrophages causes a marked reduction in pro-inflammatory macrophages in obese adipose tissue, which protects against obesity-associated IR \[[@CR5]\]. However, the molecular details that underlie ATM-driven inflammatory responses within obese adipose tissue remain uncertain.

The ClC-3 chloride channel/antiporter, encoded by *Clcn3*, is critical for several basic cellular functions, such as cell volume regulation, proliferation, apoptosis, differentiation, and β cell insulin secretion \[[@CR6]--[@CR9]\]. Accumulating evidence from animal models and human patients of inflammatory bowel disease also suggests that ClC-3 is important for inflammatory processes \[[@CR10]\]. Knockdown or genetic deletion of *Clcn3* attenuates the NF-κB activity and inflammatory responses induced by different cytokines, such as TNF-α and IL-1β, in the vascular system and lung \[[@CR11]\], thus highlighting the role of *Clcn3* deficiency in restricting inflammatory responses, particularly under diseased conditions.

Our previous study has shown that the loss of *Clcn3* significantly decreases the plasma levels of glucose, triglyceride (TG), and free fatty acid (FFA) and protects against IR compared with wild-type mice in a type 2 diabetes mouse model induced by a high sucrose/fat diet following low-dose streptozotocin \[[@CR12]\]. However, it is not clear whether and how *Clcn3* is involved in the essential functions of ATMs during obesity. In the present study, we established a high fat diet (HFD)-induced obesity model in *Clcn3*^*−/−*^ (KO) mice and investigated the effects of *Clcn3* on HFD-induced obesity and obesity-associated ATM inflammation. Collectively, our results demonstrated that *Clcn3* is associated with HFD-induced obesity and macrophage-mediated inflammatory responses in visceral fat tissue during obesity.

Materials and methods {#Sec2}
=====================

Animals {#Sec3}
-------

All experimental procedures were approved by the Sun Yat-sen University Animal Care and Use Committee and were in accordance with the "Guide for the Care and Use of Laboratory Animals" issued by the Ministry of Science and Technology of China. *Clcn3*^*−/−*^ (KO) and littermate control (WT) mice were kindly provided by Dr. Dean Burkin from the Nevada Transgenic Center (University of Nevada School of Medicine, Nevada, USA). Heterozygous 129/SvJ-C57BL/6 offspring were used to establish breeding colonies as previously described \[[@CR13]\].

Mice (8 weeks old) were fed a high-fat diet (HFD, 60% calories from fat, D12492; Research Diets Inc., USA) or a normal chow diet (NC, 10% calories from fat, D12450; Research Diets Inc., USA) for 4 or 16 weeks. At the end of the diet intervention, blood samples, livers, and epididymal fat pads were collected and stored.

Measurements of metabolic parameters {#Sec4}
------------------------------------

The following experiments were performed as previously described \[[@CR12]\]. The serum total cholesterol (TC), triglyceride (TG), free fatty acid (FFA), and C-reactive protein (CRP) levels were detected using an automated biochemical analyzer (Hitachi 7180, Japan). The fasting blood glucose levels were measured using a glucometer (Roche Diagnostics, USA). The serum level of insulin was measured with a mouse insulin ELISA kit (Nanjing Jiancheng Bioengineering Institute, China). For the intraperitoneal glucose tolerance test (PGTT), mice fasted overnight were injected with *D*-glucose (2 g/kg body weight; Sigma-Aldrich, USA). For the insulin tolerance test (ITT), mice were fasted for 5 h with free access to water and injected with insulin (0.75 units/kg body weight; Novolin R, Novo Nordisk, Copenhagen, Denmark). Blood was collected from the tail at specific time intervals, and glucose was measured using a glucometer (Roche Diagnostics, USA).

Micro-computed tomography (Micro-CT) {#Sec5}
------------------------------------

Lower abdominal computed tomography (CT, Inveon Micro-PET/CT, Siemens, Germany) scans were performed after 4 or 16 weeks of the NC or HFD. Mice were anesthetized with pentobarbital (50 mg/kg) prior to the Micro-CT scanning. The lower abdomen was defined as the level from the fourth lumbar vertebra (L4) to the coccygeal vertebra. The total lower abdomen adipose tissue volume and body volume were calculated using the regions of interest (ROI) by the Inveon Research Workplace software. Adipose tissue was defined by thresholding from −600 to −350 hounsfield unit (HU) on CT scans with manually segmentation. The ratio of the total adipose tissue volume/body volume was calculated \[[@CR14]\].

Immunohistochemistry staining {#Sec6}
-----------------------------

The epididymal white adipose tissue (eWAT) and the liver tissue were fixed in 4% paraformaldehyde (Sigma-Aldrich, USA). The liver sections were stained with Hematoxylin and Eosin (H&E) as previously described \[[@CR15]\]. The macrophage accumulation in eWAT sections was determined by immunohistochemical staining using an antibody against F4/80 (Spring Bioscience, China). The integral optical density (IOD) of the F4/80 cells (IOD sum/area) in each section was measured using Image-Pro Plus 6.0 (Media Cybernetics Corporation, Rockville, MD, USA). The average IOD of at least three section values was obtained as the mean IOD of a sample.

Flow cytometry analysis {#Sec7}
-----------------------

To block mouse Fc receptors, the cell suspension was incubated with FcBlock in Staining Buffer (5 μg/mL at a cell density of 1 × 10^6^/mL, BD Biosciences, USA) for 15 min on ice. The pellets were subsequently labeled with fluorophore-conjugated antibodies, including APC-eFluor® 780--conjugated F4/80 (eBioscience, USA), PE-conjugated CD11c (eBioscience, USA), and Alexa Fluor® 647-conjugated CD206 (Biolegend, China). The background fluorescence was quantified using an APC IgG к isotype control (eBioscience, USA), PE IgG isotype control (Invitrogen, USA), and Alexa Fluor® 647 IgG к isotype control (BioLegend, USA). Cells were measured on a Beckman Gallios flow cytometer and analyzed using Kaluza software (Beckman Coulter, USA).

Adipose stromal vascular fraction isolation {#Sec8}
-------------------------------------------

Epididymal WAT was excised and minced in PBS with 0.5% BSA. It was subsequently incubated in digestion buffer (DMEM, 12.5 mM HEPES \[pH 7.4\], 2% BSA, and 10 mg collagenase type I \[Sigma-Aldrich, USA\]) for 40 min at 37 °C in a shaking bath at 150 r/min. The digested tissue was filtered through a 250 μm nylon sieve and centrifuged at room temperature at 500 × *g* for 5 min. The pellet was washed with RBC lysis solution (Beyotime, China) and centrifuged at 500 × *g* for 5 min to remove free erythrocytes. The cell suspension was washed with PBS and spun at 300 × *g* for 5 min to obtain stromal vascular fraction (SVF) cells. The SVF provides a rich source of ATMs that exhibit a typical macrophage phenotype and are positive for F4/80, CD11c and CD206.

Cell culture {#Sec9}
------------

Human THP-1 monocytes (American Type Culture Collection, USA) were cultured in RPMI-1640 medium that contained 10% (v/v) fetal bovine serum (FBS) and 1% (w/v) penicillin/streptomycin. For monocyte--macrophage differentiation, cells were seeded at a density of 2 × 10^5^ cells/mL and exposed to 100 nM phorbol-12-myristate-13-acetate (PMA) (Sigma-Aldrich, USA) for 72 h.

Adenoviral infection experiments {#Sec10}
--------------------------------

The adenovirus expressing a small hairpin RNA sequence (Ad-sh*Clcn3*) targeting the human *Clcn3* and recombinant adenoviral vector overexpressing guinea pig *Clcn3* cDNA (Ad- *Clcn3*) was successfully constructed by Shanghai Sunbio Biomedical Technology (Shanghai, China). The sequence of the shRNA against the human *Clcn3* (Gene ID: NM_001243374.1) was 5′-CCACGACTGGTTTATCTTT-3′, which has an identity of 100% with Homo sapiens Clcn3 mRNA. The control shRNA (Neg) shows no significant homology to known human genes. The sequence of the negative control was 5′-TTCTCCGAACGTGTCACGT-3′. The guinea pig cDNA of *Clcn3* was generously gifted by Dr. Dayue Duan (University of Nevada, Reno, USA) for constructing Ad-*Clcn3*. Adenoviral infection was carried out as previously described \[[@CR16]\]. The adenoviral vector (Vector) without expressing *Clcn3* was employed as the negative control. Cells at 50% confluence were infected with Ad-sh*Clcn3* or Ad-*Clcn3* for 6 h and then washed and incubated in fresh medium for an additional 30 h prior to the addition of LPS (100 ng/mL) for 12 h.

Quantitative real-time RT-PCR {#Sec11}
-----------------------------

The quantitative real-time PCR experiment was conducted as previously described \[[@CR12]\]. Total RNA was extracted from eWAT or SVF cells using Trizol reagent (Invitrogen, USA). RNA was reverse-transcribed using the Transcriptor cDNA Synthesis Kit (Roche, USA). Quantitative RT-PCR was performed using the FS Universal SYBR Green Master (Roche, USA) according to the manufacturer's protocol. The fold change in the mRNA expression of each gene was determined by the 2^−ΔΔCt^ method using *GAPDH* mRNA as an internal control. The primer sequences are provided in Supplementary Table [1](#MOESM1){ref-type="media"}.

Western blotting {#Sec12}
----------------

eWAT or THP-1 macrophages were harvested using RIPA lysis buffer (Beyotime, China), and immunoblots were performed as previously described \[[@CR12]\]. Briefly, the samples were separated on 8% SDS polyacrylamide gels and then transferred to the nitrocellulose membrane. The membrane was incubated with the corresponding primary antibodies overnight, followed by appropriate horseradish peroxidase-conjugated secondary antibodies for 1.5 h. The bands were detected by an enhanced chemiluminescence (ECL) detection system (Beyotime, China). The images of the chemiluminescence were captured with an imaging system (Bio-Rad, Hercules, CA, USA). The optical densities were normalized to those of β-actin, and the fold difference for each target protein was calculated as the ratio of the target protein expression/β-actin expression (ImageJ 1.42q software, National Institutes of Health, USA). The primary antibodies are shown as follows: ClC-3 (1:200, Alomone Labs, Israel), TLR-4 (1:500, Santa Cruz Biotechnology, USA), NF-κB p65 (1:1000, Cell Signaling Technology, USA), p-NF-κB p65 (1:1000, Cell Signaling Technology, USA), IRS-1 (1:500, Santa Cruz Biotechnology, USA), p-IRS-1 (1:500, Santa Cruz Biotechnology, USA), and β-actin (1:2000, Cell Signaling Technology, USA).

Statistical analysis {#Sec13}
--------------------

All data are expressed as the mean ± SEM. Unpaired Student's *t*-test was used to compare 2 groups. A one-way analysis of variance (ANOVA), followed by a Bonferroni multiple comparison post hoc test with a 95% CI, was used for 3 or more groups. The statistical significance was evaluated via analysis of variance using Prism 4 software (GraphPad Software, San Diego, CA, USA). *P* \< 0.05 was considered statistically significant.

Results {#Sec14}
=======

Loss of *Clcn3* protects against diet-induced obesity {#Sec15}
-----------------------------------------------------

There was no protein expression of ClC-3 in the WAT, liver and skeletal muscle in KO mice, as detected by Western blotting (Fig. [S1a](#MOESM1){ref-type="media"}). The HFD-induced obesity model was established in *Clcn3*^+*/*+^ wild-type (WT) and *Clcn3*^*−/−*^ knockout (KO) mice. As shown in Fig. [1a, b](#Fig1){ref-type="fig"}, the *Clcn3* mRNA and protein levels were significantly increased in eWAT from obese mice after the 4-week-HFD compared with those of the age-matched NC-fed groups (*P* \< 0.05). Moreover, more significant increases in the mRNA and protein levels of *Clcn3* were shown in eWAT from WT-HFD mice after the 16-week-HFD compared with those of the age-matched NC-fed groups (*P* \< 0.01). There was no difference in body weight between WT and KO mice fed the NC; moreover, there was no difference in the total calorie intake among all groups during the feeding period (Fig. [1c, d](#Fig1){ref-type="fig"}). These results might exclude the influence from global *Clcn3* knockout on eating behavior that may be due to the degeneration of hippocampal neurons where adipocyte derived leptin has binding sites \[[@CR17]\]. Body weight in WT mice progressively increased from 4 weeks of administration of the HFD onwards, which was significantly decreased by *Clcn3* deficiency from 6 weeks of administration of the HFD onwards (Fig. [1d](#Fig1){ref-type="fig"}). Measurement of the eWAT weight and quantification of the abdominal fat depot demonstrated that the eWAT weight (normalized to body weight) markedly increased from 4 weeks of the HFD onwards (*P* *\<* 0.05 vs age-matched WT-NC groups), which was significantly decreased by *Clcn3* deficiency at the end of the 16-week-HFD (Fig. [1e](#Fig1){ref-type="fig"}, *P* *\<* 0.01 *vs* age-matched WT-HFD groups). Similar inhibitory effects of *Clcn3* deficiency on the HFD-induced increase in the absolute and relative abdominal visceral adipose tissue (VAT) volumes were measured and quantified by Micro-CT (Fig. [1f](#Fig1){ref-type="fig"}). The HFD induced an increase in the absolute and relative abdominal VAT volume from 4 weeks of the HFD onwards (*P* \< 0.01 *vs* age-matched WT-NC groups), which was significantly decreased in KO-HFD mice after the 16-week-HFD (Fig. [1f](#Fig1){ref-type="fig"}, *P* \< 0.01 vs age-matched WT-HFD groups).Fig. 1*Clcn3*^*−/−*^ (KO) mice are protected against diet-induced obesity. Eight-week-old KO mice and their *Clcn3*^*+/+*^ (WT) littermates were fed the NC or HFD. Western blotting (**a**) and qRT-PCR (**b**) analyses showed a significant increase in protein and mRNA expression of *Clcn3* in eWAT of HFD-fed WT mice (WT-HFD) for 4 or 16 weeks compared with those of age-matched NC-fed WT mice (WT-NC). \**P* \< 0.05, \*\**P* \< 0.01 *vs* age-matched WT-NC group, *n* = 6 mice per group. Weekly food intake (**c**) and body weight (**d**) were measured every 2 weeks. \**P* \< 0.05 *vs* age-matched WT-NC group, ^\#^*P* \< 0.05 vs age-matched KO-HFD group, *n* = 10 mice per group. **e** The weights of eWAT from KO and WT mice were measured and normalized to body weight. \**P* \< 0.05, \*\**P* \< 0.01, *n* = 10 mice per group. **f** A lower abdomen computed tomography scan was performed, and representative image slices (L6) are shown. The adipose tissue volume and the total adipose tissue volume/total body volume ratio were calculated. \*\**P* \< 0.01, *n* = 6 mice per group

A HFD can induce ectopic fat storage and activate macrophage-driven inflammatory responses in the liver, resulting in the occurrence of obesity-related hepatic steatosis and insulin resistance. We also set out to characterize hepatic changes in WT and KO mice. Interestingly, no substantial differences in the liver weight normalized to the body weight or hepatic steatosis were observed between the WT-HFD and KO-HFD groups fed a HFD for 4 or 16 weeks, as visualized by H&E staining (Fig. [S2](#MOESM1){ref-type="media"}). These data suggested that *Clcn3* deficiency may not affect HFD-induced fatty liver.

*Clcn3* deficiency ameliorates HFD-induced glucose and lipid metabolism disorders {#Sec16}
---------------------------------------------------------------------------------

We subsequently investigated whether *Clcn3* deficiency affects HFD-induced glucose and lipid metabolism disorders. Consistent with our previous findings \[[@CR12]\], KO mice were largely protected from the HFD-induced elevation of fasting insulin (FI) and fasting blood glucose (FBG) levels compared with the age-matched WT littermates after the 16-week-HFD (Fig. [2a, b](#Fig2){ref-type="fig"}). When ITT and PGTT were performed, KO-HFD mice had a smaller area under the curve (AUC) than their corresponding WT-HFD littermates, indicating that *Clcn3* deficiency could improve glucose metabolism disorders and impair insulin sensitivity during HFD-induced obesity (Fig. [2c, d](#Fig2){ref-type="fig"}). Serine 307 phosphorylation of mouse insulin receptor substrate-1 (IRS-1) is a common mechanism of insulin signaling that contributes to IR \[[@CR18]\]. As shown in Fig. [2e](#Fig2){ref-type="fig"}, the Western blotting data indicated that *Clcn3* deficiency markedly increased the downregulation of phospho-IRS-1 (Ser307) in eWAT induced by the HFD, suggesting that *Clcn3* may play a crucial role in regulating impaired insulin signaling during obesity. In addition, the loss of *Clcn3* markedly decreased the HFD-induced elevation in the serum TG and FFA levels; however, there was no significant change in the HFD-induced total TC level (Table [1](#Tab1){ref-type="table"}). Taken together, these findings indicated that *Clcn3* deficiency improved insulin sensitivity, glucose, and lipid metabolism in diet-induced obese mice.Fig. 2KO mice are protected against HFD-induced glucose and lipid metabolism disorders. The levels of fasting insulin (**a**) and fasting blood glucose (**b**) were measured in serum samples. \*\**P* \< 0.01 vs WT-NC group. ^\#\#^*P* \< 0.01 vs KO-HFD group, *n* = 10 mice per group. ITT (**c**), PGTT (**d**) and area under the curve (AUC) analyses of KO and WT mice fed the NC or HFD for 4 or 16 weeks are shown. \**P* \< 0.05, \*\**P* \< 0.01 vs WT-NC group, ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs KO-HFD group, *n* = 10 mice per group. **e** The levels of p-IRS-1 (serine 307) and IRS-1 in eWAT of KO and WT mice were measured by Western blotting, and β-actin was used as the loading control. \*\**P* \< 0.01 vs WT-NC group. ^\#\#^*P* \< 0.01 vs KO-HFD group, *n* = 6 mice per groupTable 1Metabolic parameters of *Clcn3*^*−/−*^ (KO) and WT mice fed a NC or HFD0 Weeks4 Weeks16 Weeks(mM)WTKOWT-NCKO-NCWT-HFDKO-HFDWT-NCKO-NCWT-HFDKO-HFDSerum TG0.26 ± 0.040.22 ± 0.210.23 ± 0.020.20 ± 0.020.43 ± 0.05\*\*0.38 ± 0.010.45 ± 0.140.38 ± 0.200.81 ± 0.42\*\*0.50 ± 0.12^\#\#^Serum TC1.14 ± 0.311.05 ± 0.181.28 ± 0.201.26 ± 0.151.70 ± 0.15\*1.60 ± 0.211.53 ± 0.371.74 ± 0.282.41 ± 0.32\*\*2.14 ± 0.10Serum FFA0.75 ± 0.080.66 ± 0.031.20 ± 0.181.27 ± 0.311.72 ± 0.25\*1.57 ± 0.341.26 ± 0.201.35 ± 0.122.58 ± 0.43\*\*1.82 ± 0.19^\#\#^\**P* \< 0.05, \*\**P* \< 0.01 vs WT-NC group^\#\#^*P* \< 0.01 vs WT-HFD group

*Clcn3* deficiency reduces HFD-induced ATM accumulation and F4/80^+^CD11c^+^CD206^−^ ATMs {#Sec17}
-----------------------------------------------------------------------------------------

HFD-fed obese mice exhibit the accumulation of adipose tissue macrophages (ATMs) and an increase in M1-like ATMs in eWAT, which are biomarkers of adipose tissue inflammation during the development of IR \[[@CR19]\]. We performed the immunofluorescent staining of ClC-3 and F4/80, a typical macrophage marker in eWAT isolated from WT-HFD mice after the 16-week-HFD, indicating a cell type-specific location of *Clcn3* in ATMs (Fig. [S3](#MOESM1){ref-type="media"}). Immunohistochemical staining showed that the HFD induced an increase of the total numbers of F4/80^+^ macrophages in eWAT from WT-HFD mice compared with the age-matched WT-NC at the end of the 16-week-HFD, which could be markedly reduced by *Clcn3* deficiency (Fig. [3a](#Fig3){ref-type="fig"}). There was no significant difference in the total number of F4/80^+^ eWAT macrophages among WT and KO mice fed the NC or HFD for 4 weeks (Fig. [3a](#Fig3){ref-type="fig"}). Flow cytometry analysis of eWAT and SVF further identified that *Clcn3* deficiency markedly reduced the HFD-induced increase in F4/80 positive cells within visceral adipose tissue during obesity (Fig. [3b](#Fig3){ref-type="fig"}). These results indicated that the loss of *Clcn3* decreases obesity-induced ATM accumulation, and this effect may be related to the time duration of the HFD.Fig. 3KO mice exhibit a decreased number of ATMs in eWAT from obese mice after 16-week-HFD. **a** Histological analysis of F4/80 staining in eWAT of KO and WT mice was used to determine ATM accumulation (scale bars represent 100 μm). The mean IODs of macrophages stained with an anti-F4/80 antibody were obtained. **b** Flow cytometry was used to quantify the effect of *Clcn3* deficiency on F4/80^+^ macrophage accumulation in SVF cells isolated from eWAT of KO and WT mice fed the NC or HFD for 16 weeks. \*\**P* \< 0.01, *n* = 6--8 mice per group

We further investigated whether *Clcn3* deficiency affects pro-inflammatory and anti-inflammatory ATM subpopulations following HFD consumption. The flow cytometry analysis demonstrates that the cell numbers of typical M1 ATMs (F4/80^+^CD11c^+^CD206^−^ cells) in the SVF from eWAT were significantly reduced in KO-HFD mice compared with their corresponding WT-HFD group (Fig. [4a](#Fig4){ref-type="fig"}). The number of typical M2 ATMs (F4/80^+^CD11c^−^CD206^+^ cells) was not significantly different between the KO-HFD and WT-HFD groups (Fig. [4a](#Fig4){ref-type="fig"}). qRT-PCR analysis for various macrophage markers yielded similar results, showing that *Clcn3* deficiency significantly decreased the enhanced transcript levels of *F4/80* and *CD11c* induced by the 16-week-HFD, compared with the corresponding WT-HFD mice (*P* \< 0.01, Fig. [4b, c](#Fig4){ref-type="fig"}). There is no significant difference in the *F4/80* and *CD11c* mRNA expression between the WT-HFD and KO-HFD groups at the end of the 4-week-HFD. Of note, the *Clcn3* deficiency induced a significant increase in the *CD206* mRNA expression after the 16-week-HFD (*P* \< 0.05, Fig. [4d](#Fig4){ref-type="fig"}). These results indicate that ATMs from *Clcn3*^*−/−*^ mice are biased toward an anti-inflammatory phenotype and suggest that *Clcn3* may be involved in obesity-induced ATM polarization.Fig. 4KO mice exhibit reduced macrophage accumulation and a lower percentage of F4/80^+^CD11c^+^CD206^−^ SVF cells from eWAT of obese mice. **a** Flow cytometry was used to quantify effects of *Clcn3* deficiency on F4/80^+^CD11c^+^CD206^−^ and F4/80^+^CD11c^−^CD206^+^ macrophage subpopulations in SVF cells isolated from eWAT of KO and WT mice fed the NC or HFD for 16 weeks. \*\**P* \< 0.01, *n* = 6 mice per group. The mRNA levels of *F4/80* (**b**), *CD11c* (**c**), and *CD206* (**d**) were analyzed by qRT-PCR in SVF of eWAT from KO and WT mice fed the NC or HFD for 4 or 16 weeks. \**P* \< 0.05, \*\**P* \< 0.01, *n* = 6/group

*Clcn3* deficiency decreases systemic and adipose tissue inflammation induced by HFD {#Sec18}
------------------------------------------------------------------------------------

To determine whether *Clcn3* deficiency results in different inflammatory profiles during obesity, we also measured the levels and expression of cytokines and adipokines in the serum or eWAT from KO and WT mice (Fig. [5](#Fig5){ref-type="fig"}). The transcript levels of the examined systemic cytokines and adipose tissue cytokines (or adipokines) were not significantly different between the WT-NC and KO-NC groups, indicating that *Clcn3* deficiency had no influence on the basal production of these cytokines and chemokines in the absence of a dietary challenge (Fig. [5](#Fig5){ref-type="fig"}). The serum of HFD-fed WT mice showed an increase in C-reactive protein (CRP), indicating the induction and progression of low-grade adipose tissue inflammation. These changes were largely prevented in *Clcn3*^*−/−*^ mice after the 16-week-HFD (Fig. [5a](#Fig5){ref-type="fig"}). qRT-PCR analysis showed that *Clcn3* deficiency significantly decreased the HFD-induced increase in mRNA expression of *MCP-1*, *TLR-4,* and *IL-6* in eWAT (Fig. [5b--d](#Fig5){ref-type="fig"}). Interestingly, *Clcn3* deficiency significantly attenuated the HFD-induced increase in *MCP-1* and *TLR-4* as early as 4 weeks after HFD feeding, while it had no significant effects on the HFD-induced change in *TNF-α* and *adiponectin* (Fig. [5e, f](#Fig5){ref-type="fig"}). Tamoxifen at 10 µM has commonly been used to inhibit ClC-3-dependent Cl^−^ currents and volume-sensitive Cl^−^ movement in many cell types, including RAW macrophages \[[@CR20]\]. The qRT-PCR data demonstrated that tamoxifen causes a significant decrease in *Clcn3* and inhibits the LPS-induced increase in *MCP-1*, *TLR-4*, and *IL-6* in F4/80^+^ SVF cells isolated from mouse eWAT (Fig. [S4](#MOESM1){ref-type="media"}). These results support that the *Clcn3*-dependent Cl^−^ currents may be involved in regulating ATM inflammation. Collectively, these findings indicated that the production of pro-inflammatory mediators induced by a HFD is lower locally and systemically in KO mice than in the corresponding WT mice, suggesting a decrease in the levels of adipose inflammation in KO mice during obesity.Fig. 5KO mice demonstrate reduced levels of inflammatory mediators. **a** The serum CRP level was measured in KO mice and their WT littermates fed a NC or a HFD for 4 or 16 weeks. The mRNA levels of *MCP-1* (**b**), *TLR-4* (**c**), *IL-6* (**d**), *TNF-α* (**e**), and *adiponectin* (**f**) in eWAT were measured in KO mice and their WT littermates fed the NC or HFD. \**P* \< 0.05, \*\**P* \< 0.01, *n* = 6/group. **g** Protein expression of TLR-4 and activation of NF-κB (as indicated by the ratio of phospho-NF-κB p65 to total NF-κB p65) were measured in eWAT from KO mice and their corresponding WT littermates. *\*\*P* \< 0.01, *n* = 6--8 mice per group

*Clcn3* deficiency reduces HFD-induced activation of TLR-4 and NF-κB in eWAT {#Sec19}
----------------------------------------------------------------------------

The TLR4/NF-κB signaling pathway is enhanced in HFD-induced elevation of the LPS level and adipose tissue inflammation that links obesity to IR \[[@CR4]\]. The transcript level of *TLR-4* was alleviated in eWAT from KO mice fed a HFD (Fig. [5c](#Fig5){ref-type="fig"}). HFD feeding increased the phospho-p65 and TLR-4 protein levels in eWAT from WT mice, which were reduced in KO mice (Fig. [5g](#Fig5){ref-type="fig"}). The activation of TLR-4 and NF-κB was further investigated in macrophages derived from the THP-1 cell line, which was infected with Ad-*Clcn3* shRNA or Ad-*Clcn3*, respectively, and then treated with LPS. LPS potently increased the NF-κB activation and TLR-4 protein expression, which were largely abolished by *Clcn3* knockdown and further potentiated by *Clcn3* overexpression in THP-1 macrophages (Fig. [6a, b](#Fig6){ref-type="fig"}). Collectively, these results indicated that *Clcn3* deficiency may ameliorate adipose tissue inflammation via suppressing the activation of TLR-4 and NF-κB.Fig. 6*Clcn3* regulates LPS-induced activation of TLR-4/ NF-κB in THP-1 macrophages. The effects of adenoviral *Clcn3-shRNA* knockdown (**a**) and *Clcn3* overexpression (**b**) on protein expression of TLR-4 and phospho-NF-κB p65/total NF-κB p65 were detected by Western blotting. The respective control shRNA (Neg) and the adenoviral vector (Vector) without *Clcn3* expression were employed. *\*P* \< 0.05, *\*\*P* \< 0.01, *n* = 6 independent experiments

Discussion {#Sec20}
==========

In the present study, we have provided the first and strong evidence that downregulation of *Clcn3* was a crucial protective factor against diet-induced obesity because *Clcn3* knockout attenuated HFD-induced body weight gain, abdominal adipose volume expansion, and glucose and lipid disorders. Notably, the 4-week-HFD was shown to increase the mRNA and protein expressions of *Clcn3* in adipose tissue, as well as several pro-inflammatory cytokines (such as *MCP-1* and *TLR-4*) characteristic of adipose tissue inflammation, which could be significantly reduced in KO mice. These findings suggest that *Clcn3* may be an early contributor to the development of obesity and obesity-related adipose tissue inflammation.

Macrophage-related chronic inflammation has been implicated as a major pathogenic mechanism of adipose tissue dysfunction and consequent IR. *Clcn3* deficiency has recently been reported to prevent atherosclerotic lesion development via suppressing the uptake of ox-LDL in macrophages \[[@CR21]\], directly linking *Clcn3* to atherosclerotic lesion formation through the regulation of macrophage functions. Increased ATMs contribute to systemic IR by creating a pro-inflammatory environment. A HFD induces an increase in F4/80^+^ macrophage accumulation from both the recruitment of macrophages from the blood stream and the proliferation of itself, and it promotes the pro-inflammatory M1 macrophage polarization within abdominal visceral fat and the secretion of pro-inflammatory adipokines. Accumulating evidence in obese mouse models has documented that the inhibition of M1 macrophage polarization is an effective strategy for attenuating adipose tissue inflammation and IR \[[@CR5], [@CR22]\]. Consistent with these reports, our present study provides direct evidence showing that *Clcn3* may play an important role in obesity-associated chronic ATM inflammation because the loss of *Clcn3* significantly reduced the HFD-induced increase in the cell numbers of ATMs and F4/80^+^CD11c^+^CD206^−^ ATMs during obesity.

Obesity produces a state of chronic and low grade inflammation accompanied by elevated levels of pro-inflammatory cytokines. In this study, we observed that the transcript levels of several key inflammatory cytokines (e.g., *MCP-1* and *IL-6*) in eWAT were increased following HFD feeding in combination with a high serum CRP, thus confirming that adipose tissue serves as a primary source of inflammatory responses during obesity. The presented results demonstrated that upregulation of *TNF-α* or downregulation of *adiponectin* induced by a HFD were not affected by *Clcn3* deficiency. The result in Fig. [S2](#MOESM1){ref-type="media"} demonstrates that global *Clcn3* deficiency did not affect HFD-induced injury to the mouse liver, suggesting that the influence of *Clcn3* deficiency on obesity may be restricted to adipose tissue. Thus, it is likely that the effect of *Clcn3* on the local transcript levels of different types of inflammatory cytokines is also limited. In addition, *Clcn3* deficiency tended to increase the adiponectin mRNA expression after the 16-week-HFD; however, there is no significant difference between the WT-HFD and KO-HFD groups. It has been found that there is an association between adipose tissue hypertrophy, a lower adiponectin level and aging \[[@CR23]\]. Therefore, further investigation is required to examine the time-dependent influences of *Clcn3* on age-related adipokine levels during obesity or type 2 diabetes. In addition, the expression of *IL-6* was used to define adipose tissue inflammation. However, recent studies have demonstrated that a significant proportion of obese patients did not express typical inflammatory cytokines, such as *IL-6* and *TNF-α* \[[@CR24]\]. Moreover, oncostatin M (OSM), a member of the *IL-6* family, has been found to change the phenotypes of adipose tissue macrophages toward an anti-inflammatory M2 type. OSM may thus serve as a novel target for obesity and obesity-induced metabolic syndrome \[[@CR25], [@CR26]\]. Due to the increased complexity of obesity-related inflammatory cytokines indicated in adipose tissue, further investigation is required to evaluate the effects of *Clcn3* deficiency on the inflammatory cytokine profile during obesity.

TLR-4 has been demonstrated to be critical in adipose tissue inflammation, in which it directly targets NF-κB and, in turn, induces the release of pro-inflammatory adipokines \[[@CR4], [@CR27]\]. Of note, *Clcn3* deficiency significantly suppressed the HFD-induced increase in the *TLR-4* mRNA and protein levels in eWAT at the early stage of obesity (after 4 weeks of the HFD), suggesting that *Clcn3* may be a novel mechanism that underlies obesity-induced adipose tissue inflammation through TLR-4 signaling.

LPS is an important endogenous inflammatory mediator that underlies adipose tissue dysfunction during diet-induced obesity \[[@CR28]\]. A HFD induces an increase in the level of LPS that could cause abdominal ATM-driven inflammation, thus contributing to the impaired glucose metabolism during obesity \[[@CR29]\]. Consistent with these findings, we observed a significant increase in the serum CRP level accompanied by altered lipid metabolism in obese mice following feeding a HFD, which could be abolished by *Clcn3* deficiency. LPS has been reported to promote the secretion of pro-inflammatory cytokines through the activation of TLR-4 and its downstream NF-κB signaling in adipose tissue inflammation \[[@CR30]\]. Recently, the knockdown of *Clcn3* has been demonstrated to inhibit LPS-induced inflammation in RAW 264.7 cells by blocking the activation of TLR-4/NF-κB signaling \[[@CR31]\]. In agreement with these findings, we further demonstrated that *Clcn3* deficiency remarkably suppressed the activation of TLR-4/NF-κB in eWAT from obese mice following a HFD. Collectively, *Clcn3* may mediate local adipose tissue inflammatory responses and systemic inflammation in obese mice via the activation of TLR-4/NF-κB signaling pathways.

Previous studies in *Clcn3*^*−/−*^ mice have demonstrated that there is a decrease in systemic insulin levels or β cell insulin exocytosis, although the exact molecular mechanism remains debated \[[@CR7], [@CR17], [@CR32], [@CR33]\]. The data from our lab are in agreement with these previous reports and support that the *Clcn3* gene may be involved in the regulation of insulin secretion \[[@CR12]\]. With the exception of the rest insulin levels, our results indicated there were no abnormalities in the fasting glucose level, FFA and TG levels, glucose tolerance (PGTT), and insulin sensitivity (ITT and HOMA-IR) in global *Clcn3*^*−/−*^ mice. These findings are consistent with a previous report that hyperglycemia or rebound hypoglycemia were not present following a glucose load in *Clcn3*^*−/−*^ mice \[[@CR34]\]. Apart from the pancreas, global *Clcn3*^*−/−*^ mice show a degeneration of hippocampal neurons and an increase in the systemic leptin level \[[@CR17]\], which raise another concern regarding the neuronal influences on the eating behaviors of global *Clcn3*^*−/−*^ mice. Our results demonstrated that there is no significant difference in the body weight between WT and KO mice fed the NC; moreover, there was no significant difference in the total calorie intake among all groups during the feeding period. These findings suggested that the improvement in HFD-induced glucose and lipid disorders in KO mice may not be due to the *Clcn3* deficiency on pancreatic insulin secretion and eating behaviors, and there must be another mechanism involved in this process. Furthermore, our present data showed that *Clcn3* deficiency significantly increased the down-regulation of the serine 307 phosphorylation of IRS-1 induced by the HFD in eWAT, indicating that *Clcn3* deficiency may recover the impaired insulin signaling. Similar beneficial effects of *Clcn3* deficiency on disrupted glucose and lipid metabolism have been found in a high sucrose/fat, low-dose STZ induced T2DM mouse model \[[@CR12]\]. Together, these findings raised the interesting possibility that *Clcn3* might play a more general role in glucose and lipid metabolism disorders during the development of T2DM. Because the global *Clcn3* knockout produces complex compensatory changes, further investigation in *Clcn3* conditional knockout mouse models will be helpful to elucidate the role of *Clcn3* in obesity and obesity-associated adipose tissue inflammation and metabolic changes.

Volume-sensitive Cl^−^ channels/currents have been reported to be crucial for adipocyte hypertrophy, β cell excitability and inflammatory responses driven by immune cells and may thus be associated with adipose dysfunction \[[@CR35], [@CR36]\]. *Clcn3* has been reported to encode the Cl^−^ channel or regulate the volume-regulated Cl^−^ movement or Cl^−^ current in many cell types. The presented results from *Clcn3*^*−/−*^ mice support the relation between an abnormal Cl^−^ signal and adipose tissue dysfunction during obesity and T2DM. The inhibitory effect of tamoxifen on the LPS-induced increase in the transcript levels of inflammatory cytokines (e.g., *MCP-1*, *TLR-*4, and *IL-6*) in F4/80^+^ SVF cells isolated from mouse eWAT suggested a novel role of an abnormal Cl^−^ signal in ATM inflammation. However, SWELL 1 (leucine-rich repeats containing 8A, LRRC8A) has recently been reported to be an essential component of volume-regulated ion channels (VRACs) in adipocytes and β cells, and may serve as an endogenous regulator of insulin sensitivity and glucose homeostasis \[[@CR35], [@CR37]--[@CR39]\]. In addition, bestrophin 1 is indispensable for volume regulation in human retinal pigment epithelium cells \[[@CR40]\]. Therefore, the molecular identity for volume-sensitive Cl^−^ channels remains controversial. The discrepancy regarding the Cl^−^ channel molecular component in different cell types and distinct cell components within adipose tissue (e.g., adipocytes, preadipocytes, immune cells, and endothelial cells) suggests that the molecular components of volume-sensitive Cl^−^ channels in adipose tissue should be complicated. Caution should be employed in investigating the relation between *Clcn3* and Cl^−^ signaling, particularly under pathological conditions.

There may be limitations to the classification scheme of macrophages using CD11c because CD11c has also recently been found on adipose tissue dendritic cells (ATDCs) \[[@CR41]\]. It has been reported that ATDCs may play a role in obesity-associated adipose inflammation \[[@CR42], [@CR43]\]. Therefore, our presented results could not exclude the influence of *Clcn3* deficiency on ATDCs. Further investigation with specific macrophage markers, such as CD64, will be helpful to differentiate ATMs from ATDCs.

In conclusion, the present study identified that *Clcn3* is a novel mechanism to regulate HFD-induced obesity and adipose tissue inflammatory responses. *Clcn3* may thus be involved in the development of diet-induced obesity and associated lipid and glucose metabolism disorders. These results also suggest that modulation of *Clcn3* may provide an appealing therapeutic target for obesity and type 2 diabetes.
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